All In Biotech

Drug Trial Radar · NCT06082102

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Dec 19, 2023

Primary completion

Aug 31, 2028

Study completion Feb 25, 2030

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Conditions

  • Relapsed/Refractory Marginal Zone Lymphoma

Interventions

  • OrelabrutinibDrug

    Orelabrutinib Tablets

  • RituximabDrug

    Rituximab Injection

  • LenalidomideDrug

    Lenalidomide Capsules

  • RituximabDrug

    Rituximab Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IRC-assessed PFSTime frame: Through study completion, an average of 5 year.

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Auhui, China · Recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial Hospital of Chinese Medicine

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Henan Provincial Peoples Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • The first Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • The Affiliated Hospital Of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)

    Xi’an, Shanxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.